Dr. Marcus S. Noel, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 184
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 257169 -
Hematology & Oncology Physician
NY license 257169 -
Hospitalist Physician
NY license 257169
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Washington Hospital Center Washington, DC
- Medstar Georgetown University Hospital Washington, DC
- Medstar Saint Mary's Hospital Leonardtown, MD
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 184
- Services billed
- 520
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 267 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 103 | 60 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 23 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Rochester, NY | 37 |
| Eliquis (apixaban) Other prescribers in Rochester, NY | 35 |
| Ondansetron Hcl Other prescribers in Rochester, NY | 33 |
| Creon (lipase/protease/amylase) Other prescribers in Rochester, NY | 27 |
| Gabapentin Other prescribers in Rochester, NY | 25 |
| Imatinib Mesylate | 23 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Rochester, NY | 13 |
| Qinlock (ripretinib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 11 payments worth $6,071 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $5,047 |
|---|---|
| Astellas Pharma US Inc | $754 |
| AstraZeneca Pharmaceuticals LP | $112 |
| E.r. Squibb & Sons, L.l.c. | $71.74 |
| Deciphera Pharmaceuticals Inc. | $32.68 |
| Beone Medicines USA, Inc. | $18.80 |
| Tersera Therapeutics LLC | $18.17 |
| Regeneron Healthcare Solutions, Inc. | $17.02 |
| Consulting Fee | $5,647 |
|---|---|
| Food and Beverage | $407 |
| Education | $17.02 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Mar 31, 2025 | Consulting Fee Stivarga · Oncology | $2,884 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 26, 2025 | Consulting Fee Stivarga · Oncology | $2,163 |
| Astellas Pharma US Inc Feb 8, 2025 | Consulting Fee Vyloy · Oncology | $600 |
| Regeneron Healthcare Solutions, Inc. Feb 28, 2025 | Education LIBTAYO · ONCOLOGY · in-kind | $17.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $464,335 in research payments for these studies, mostly to the institutions running them.
- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
AstraZeneca UK Limited - Fruquintinib
Takeda Pharmaceuticals U.S.A., Inc. - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib E7080,MK-7902 plus Pembrolizumab MK-3475 plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participant…
Merck Sharp & Dohme LLC - A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
Pfizer Inc. - A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Astellas Pharma Inc - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576 - Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
E.r. Squibb & Sons, L.l.c. · Completed · NCT04039607 - A phase 3, open-label, randomized study of perioperative dostarlimab m
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.